Revenue and profit growth driven by healthcare-related demand in the United States
First written in FY2021-Q1. 2 of 4 entries say "Restated". Latest entry: FY2022-Q2.
0 other companies' latest entry also says "Dropped".
- FY2022-Q2DroppedAnnual report
「(U.S.) Revenue was ¥1,937.035 million, up 14.8% year on year, and operating profit was ¥265.152 million, up 1.8% year on year.」
The U.S. segment posted higher revenue and operating profit, but this filing does not explicitly cite the previously stated strength of the medical-related business as the driver, instead presenting the results as those of the U.S. business overall. - FY2021-Q3RestatedAnnual report
「(U.S.) As medical-related business remained strong, revenue was ¥2,670.367 million, up 18.1% year on year, and operating profit was ¥390.752 million, up 79.4% year on year.」
The U.S. business continues to post higher revenue and operating profit, supported by strong medical-related business. - FY2021-Q2RestatedAnnual report
「(U.S.) As medical-related business remained strong, revenue was ¥1,687.061 million, up 5.9% year on year, and operating profit was ¥260.407 million, up 64.1% year on year.」
The U.S. business continues to post higher revenue and operating profit, supported by strong medical-related business. - FY2021-Q1First statedAnnual report
「(U.S.) As medical-related business remained strong, revenue was ¥956.727 million, up 11.7% year on year, and operating profit was ¥169.843 million, up 52.1% year on year.」
For the first time, the filing states that the U.S. segment posted higher revenue and operating profit on the strength of its medical-related business.